{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:36Z","timestamp":1793286216029,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,18]]},"DOI":"10.7759\/cureus.45455","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T12:32:17Z","timestamp":1695040337000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Pembrolizumab-Induced Myasthenia Gravis"],"prefix":"10.7759","author":[{"given":"Thomas I","family":"Kosick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krima","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Jasinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Dada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref2","article-title":"Diagnosis of myasthenia gravis","author":"Bird SJ","year":"2023","unstructured":"Bird SJ. Diagnosis of myasthenia gravis. UpToDate. Post TW (ed): UpToDate, Waltham; 2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15174","article-title":"Pembrolizumab-associated seronegative myasthenia gravis in a patient with metastatic renal cell carcinoma","volume":"13","author":"Pandya SK","year":"2021","unstructured":"Pandya SK, Ulrickson M, Dong J, Willen R, Pandya A. Pembrolizumab-associated seronegative myasthenia gravis in a patient with metastatic renal cell carcinoma. Cureus. 2021, 13:e15174. 10.7759\/cureus.15174","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nm0817-1004b","article-title":"Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?","volume":"23","author":"June CH","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA. Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?. Nat Med. 2017, 23:1004. 10.1038\/nm0817-1004b","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14740\/jmc4008","article-title":"Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors","volume":"13","author":"Schwab A","year":"2022","unstructured":"Schwab A, Assaad M, Hamadi R, et al.. Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors. J Med Cases. 2022, 13:530-5. 10.14740\/jmc4008","journal-title":"J Med Cases"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino M","year":"2018","unstructured":"Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018, 6:e00355. 10.1002\/rcr2.355","journal-title":"Respirol Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26021","article-title":"Refractory myasthenia gravis exacerbation triggered by pembrolizumab","volume":"57","author":"Earl DE","year":"2018","unstructured":"Earl DE, Loochtan AI, Bedlack RS. Refractory myasthenia gravis exacerbation triggered by pembrolizumab. Muscle Nerve. 2018, 57:E120-1. 10.1002\/mus.26021","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02722-8","article-title":"Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report","volume":"15","author":"Tian CY","year":"2021","unstructured":"Tian CY, Ou YH, Chang SL, Lin CM. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. J Med Case Rep. 2021, 15:244. 10.1186\/s13256-021-02722-8","journal-title":"J Med Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March KL","year":"2018","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2018, 24:146-9. 10.1177\/1078155216687389","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-215012","article-title":"Limbic encephalitis following immunotherapy against metastatic malignant melanoma","volume":"2016","author":"Salam S","year":"2016","unstructured":"Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016, 2016:10.1136\/bcr-2016-215012","journal-title":"BMJ Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye MF","year":"2016","unstructured":"de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016, 375:296-7. 10.1056\/NEJMc1515584","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson DB","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, et al.. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019, 7:134. 10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang YT","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020, 11:634. 10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh S","year":"2019","unstructured":"Trinh S, Le A, Gowani S, La-Beck NM. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines. Asia Pac J Oncol Nurs. 2019, 6:154-60. 10.4103\/apjon.apjon_3_19","journal-title":"Asia Pac J Oncol Nurs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170366-a-case-of-pembrolizumab-induced-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:31Z","timestamp":1707509131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170366-a-case-of-pembrolizumab-induced-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.45455","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}